Clinical Trial Update: To Evaluate 2 Doses of GSK Biologicals' Oral Live Attenuated Human HRV Vaccine Co-administered With Either OPV or IPV [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated two doses of GlaxoSmithKline's oral live attenuated human rotavirus vaccine co-administered with OPV or IPV; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rotavirus Infections

Drugs mentioned

• Rotarix (Rotavirus vaccine (live attenuated))

Snippet

Sponsor: GlaxoSmithKline | Conditions: Rotavirus Infections | Phase 2 | Status: COMPLETED